Researchers from Oxford University Hospitals NHS Trust Report Details of New Studies and Findings in the Area of Waldenstrom Macroglobulinemia (Pembrowm: a Phase Ii Trial To Investigate the Safety and Efficacy of Rituximab and Pembrolizumab In...).

A recent study conducted by researchers from Oxford University Hospitals NHS Trust in the United Kingdom explored the use of rituximab and pembrolizumab in patients with relapsed/refractory Waldenstrom Macroglobulinemia (WM). The study involved 17 patients who had previously received treatment and showed promising results. The overall response rate was 50%, with a median duration of response of 11.6 months. The treatment was well-tolerated, and the study concluded that the combination of rituximab and pembrolizumab is safe and effective in WM patients. This research provides valuable insights into potential treatment options for WM. [Extracted from the article]